AbbVie Inc (ABBV)
203.24
-0.84
(-0.41%)
USD |
NYSE |
Feb 25, 16:00
205.21
+1.97
(+0.97%)
After-Hours: 18:46
Key Stats
Price and Performance | |
---|---|
Market Cap | 358.79B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 18.83% |
Valuation | |
PE Ratio | 84.68 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 6.397 |
Price to Book Value | 107.91 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 1.64 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 20.19 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 42.18% |
Profile
Edit
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). |
URL | https://www.abbvie.com |
Investor Relations URL | https://investors.abbvie.com |
HQ State/Province | Illinois |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | Apr. 25, 2025 (est.) |
Last Earnings Release | Jan. 31, 2025 |
Next Ex-Dividend Date | Apr. 15, 2025 |
Last Ex-Dividend Date | Jan. 15, 2025 |
Ratings
Profile
Edit
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). |
URL | https://www.abbvie.com |
Investor Relations URL | https://investors.abbvie.com |
HQ State/Province | Illinois |
Sector | Health Care |
Industry | Biotechnology |
Next Earnings Release | Apr. 25, 2025 (est.) |
Last Earnings Release | Jan. 31, 2025 |
Next Ex-Dividend Date | Apr. 15, 2025 |
Last Ex-Dividend Date | Jan. 15, 2025 |